In summary, this retrospective analysis applied to a prospective clinical trial demonstrated that TIMP-1 status appears to contain an independent prognostic value regarding overall survival in patients with advanced breast cancer receiving chemotherapy. This evidence concerns the gene TIMP1 and breast cancer.